Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Research & Development (2020 - 2025)

Historic Research & Development for Neuroone Medical Technologies (NMTC) over the last 6 years, with Q4 2025 value amounting to $1.4 million.

  • Neuroone Medical Technologies' Research & Development rose 1855.03% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 million, marking a year-over-year increase of 939.66%. This contributed to the annual value of $5.0 million for FY2025, which is 161.53% down from last year.
  • Latest data reveals that Neuroone Medical Technologies reported Research & Development of $1.4 million as of Q4 2025, which was up 1855.03% from $1.1 million recorded in Q3 2025.
  • Over the past 5 years, Neuroone Medical Technologies' Research & Development peaked at $1.9 million during Q2 2023, and registered a low of $901134.0 during Q2 2021.
  • Over the past 5 years, Neuroone Medical Technologies' median Research & Development value was $1.2 million (recorded in 2022), while the average stood at $1.3 million.
  • In the last 5 years, Neuroone Medical Technologies' Research & Development soared by 5436.49% in 2023 and then plummeted by 3741.46% in 2024.
  • Neuroone Medical Technologies' Research & Development (Quarter) stood at $1.1 million in 2021, then soared by 47.44% to $1.6 million in 2022, then dropped by 5.13% to $1.5 million in 2023, then dropped by 20.97% to $1.2 million in 2024, then rose by 18.55% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q4 2025, $1.1 million for Q3 2025, and $1.2 million during Q2 2025.